Screener
Monopar Therapeutics MNPR Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Monopar Therapeutics’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 2:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001437749-26-016982
| Line item | For the Three Months Ended / March 31, 2026 | For the Three Months Ended / March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income (loss) | $(3,893,050) | $(2,624,972) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Stock-based compensation expense | 1,692,980 | 1,355,017 |
| Net amortization of investment discounts and premiums | (799,634) | (119,509) |
| Changes in operating assets and liabilities, net | ||
| Other current assets | (187,039) | (502,034) |
| In-process research and development accrued expenses | — | (3,000,000) |
Document
FAQ
- What is Monopar Therapeutics's stock-based comp?
- Monopar Therapeutics (MNPR) reported stock-based comp of $1.69M in Q1 2026.
- How has Monopar Therapeutics's stock-based comp changed year-over-year?
- Monopar Therapeutics's stock-based comp increased by 24.9% year-over-year, from $1.36M to $1.69M.
- What is the long-term trend for Monopar Therapeutics's stock-based comp?
- Over 3 years (2022 to 2025), Monopar Therapeutics's stock-based comp has grown at a 43.4% compound annual growth rate (CAGR), from $1.64M to $4.84M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Monopar Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude